CDER's 2017 New Drug Class Maintains Steady Innovative Composition With Recent Years
New drugs approved in 2017 were not significantly different than those from years past in terms of innovative characteristics, but accelerated approval percentage took a sharp drop.
You may also be interested in...
Orphan drugs and priority reviews achieved historic highs in CDER's 2018 novel approval class, but share of products with breakthrough therapies took a slide.
With at least 40 pending novel products, FDA seems poised to break its 2017 approval record of 46, and could even reach 60.
Second go-round for oral testosterone could have marked new boundary on how far FDA is willing to go in approving new entrants to a market with widespread historic off-label use and CV risks.